#dive

Related news

Alnylam soars on trial win for RNAi drug

Published: 20/09/2017

Patisiran's success marks a major milestone for the Cambridge biotech, which has spent 15 years developing the science behind its RNA interference approach. Read more

Source: www.biopharmadive.com
Juniper rushes to save costs with job cuts

Published: 19/09/2017

Women's health company Juniper is focusing to its core program, cutting jobs and seeking partners in a bid to increase cash flow. Read more

Source: www.biopharmadive.com
Catalent adds biologics manufacturing with $950M Cook Pharmica deal

Published: 19/09/2017

The contract developer is expanding its capabilities to encompass development through commercialization. Read more

Source: www.biopharmadive.com

Supernus tweaks ADHD studies to boost chances of success

Published: 19/09/2017

A planned interim analysis prompted the Maryland specialty pharma to drop a low dose of its drug for impulsive aggression in two Phase 3 trials. Read more

Source: www.biopharmadive.com
Teva offloads the rest of its women's health business for $1.4B

Published: 19/09/2017

The deals put Teva past its goal of selling $2 billion worth of assets by year's end. Read more

Source: www.biopharmadive.com
GSK's respiratory business boosted by lung drug approval

Published: 19/09/2017

The three-in-one inhaler should help GlaxoSmithKline stay competitive in respiratory disease as rival therapies erode sales of its blockbuster drug Advair. Read more

Source: www.biopharmadive.com

AbbVie, Roche to seek broader market for leukemia drug after trial success

Published: 18/09/2017

The drugmakers hope Venclexta could replace chemotherapy in combination treatment of relapsed, refractory CLL patients. Read more

Source: www.biopharmadive.com
How to optimize pharma sales forces in a changing marketplace

Published: 18/09/2017

Less time with doctors, an increase in rare disease drugs and higher use of digital tools means it's important to find the right talent and use reps efficiently. Read more

Source: www.biopharmadive.com
Smaller sales forces get the job done in rare disease

Published: 18/09/2017

The shift from primary care to specialty medicines has meant rightsizing sales forces to match markets. Read more

Source: www.biopharmadive.com

Infographic: Pharma sales force by the numbers

Published: 18/09/2017

As sales force numbers have declined across the industry, pharma is looking to new ways to reach physicians. Read more

Source: www.biopharmadive.com
Ultragenyx trying to snag Regenxbio's takeover target

Published: 18/09/2017

Dimension Therapeutics now has another buyout offer to consider. Read more

Source: www.biopharmadive.com
Nabriva shares leap higher on antibiotic trial success

Published: 18/09/2017

Positive results from Nabriva's LEAP 1 study augur well for the potential of the company's novel anti-infective in a common type of bacterial pneumonia. Read more

Source: www.biopharmadive.com

FDA places two combo studies of Roche's Tecentriq on partial hold

Published: 18/09/2017

The decision follows recruitment halts for a number of other trials involving PD-(L)1 inhibitors in certain blood cancers due to safety concerns. Read more

Source: www.biopharmadive.com
Samsung Bioepis first to secure EMA backing for Herceptin biosimilar

Published: 15/09/2017

A final decision on marketing authorization will be made by the European Commission in the coming months. Read more

Source: www.biopharmadive.com
Bayer's PI3K inhibitor secures FDA approval

Published: 15/09/2017

The regulatory OK was supported by a mid-stage study which showed efficacy in heavily pretreated patients with follicular lymphoma. Read more

Source: www.biopharmadive.com

Amgen, Allergan win first approval of cancer biosimilar in US

Published: 14/09/2017

The drug, which will be marketed as Mvasi, is a biosimilar version of Roche's top-selling biologic Avastin. Read more

Source: www.biopharmadive.com
AstraZeneca's Bydureon falls short in heart study

Published: 14/09/2017

Lack of a heart benefit means a comeback for Bydureon probably isn't in the cards. Read more

Source: www.biopharmadive.com
Fujifilm opens new mammalian cell facility

Published: 14/09/2017

The 10,000-square-foot facility expands the Japanese firm's footprint in the U.K. Read more

Source: www.biopharmadive.com

FDA calls for industry input on continuous manufacturing guidelines

Published: 14/09/2017

Biopharmas largely haven't adopted the speedier and more adaptable approach to drug manufacturing, relying instead on tried-and-true batch production methods. Read more

Source: www.biopharmadive.com
Lilly's baricitinib fails to outshine Sanofi's Dupixent

Published: 14/09/2017

A mid-stage study in atopic dermatitis hit statistical significance, but results appeared to fall short of the mark set by Sanofi and Regeneron's already approved treatment. Read more

Source: www.biopharmadive.com
Pfizer, Astellas eye wider market for prostate cancer drug

Published: 14/09/2017

Xtandi's broader commercial prospects were a key factor in Pfizer's decision to pick up the drug in a $14 billion acquisition of Medivation last fall. Read more

Source: www.biopharmadive.com

Related Hashtags

Most read

FACEBOOK

Facebook

Place your ad here
Loading...